JP5180477B2 - デスモプレシンを含有するブリスターパック及び固形製剤 - Google Patents
デスモプレシンを含有するブリスターパック及び固形製剤 Download PDFInfo
- Publication number
- JP5180477B2 JP5180477B2 JP2006538867A JP2006538867A JP5180477B2 JP 5180477 B2 JP5180477 B2 JP 5180477B2 JP 2006538867 A JP2006538867 A JP 2006538867A JP 2006538867 A JP2006538867 A JP 2006538867A JP 5180477 B2 JP5180477 B2 JP 5180477B2
- Authority
- JP
- Japan
- Prior art keywords
- acid
- blister pack
- blister
- desmopressin
- solid formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 title claims abstract description 27
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 title claims abstract description 24
- 229960004281 desmopressin Drugs 0.000 title claims abstract description 22
- 239000007787 solid Substances 0.000 title claims description 32
- 238000002360 preparation method Methods 0.000 title claims description 15
- 150000003839 salts Chemical class 0.000 claims abstract description 6
- 239000002671 adjuvant Substances 0.000 claims abstract description 4
- 239000003085 diluting agent Substances 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims description 30
- 238000009472 formulation Methods 0.000 claims description 20
- 239000002253 acid Substances 0.000 claims description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 11
- 229910052782 aluminium Inorganic materials 0.000 claims description 11
- 239000011888 foil Substances 0.000 claims description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 7
- 239000004743 Polypropylene Substances 0.000 claims description 7
- 229920001328 Polyvinylidene chloride Polymers 0.000 claims description 7
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 7
- 239000001630 malic acid Substances 0.000 claims description 7
- 235000011090 malic acid Nutrition 0.000 claims description 7
- 239000005033 polyvinylidene chloride Substances 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 239000002702 enteric coating Substances 0.000 claims description 5
- 238000009505 enteric coating Methods 0.000 claims description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims description 4
- 235000015165 citric acid Nutrition 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000004952 Polyamide Substances 0.000 claims description 3
- 239000004698 Polyethylene Substances 0.000 claims description 3
- 229920002647 polyamide Polymers 0.000 claims description 3
- 229920000728 polyester Polymers 0.000 claims description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 2
- 239000004793 Polystyrene Substances 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- 235000011054 acetic acid Nutrition 0.000 claims description 2
- 239000001361 adipic acid Substances 0.000 claims description 2
- 235000011037 adipic acid Nutrition 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 235000003704 aspartic acid Nutrition 0.000 claims description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000004220 glutamic acid Substances 0.000 claims description 2
- 235000013922 glutamic acid Nutrition 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 235000011007 phosphoric acid Nutrition 0.000 claims description 2
- 229920002223 polystyrene Polymers 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- 235000011167 hydrochloric acid Nutrition 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 claims 1
- 239000007909 solid dosage form Substances 0.000 abstract description 6
- 230000015556 catabolic process Effects 0.000 abstract description 3
- 238000006731 degradation reaction Methods 0.000 abstract description 3
- 239000004800 polyvinyl chloride Substances 0.000 description 12
- 229920000915 polyvinyl chloride Polymers 0.000 description 11
- MLSVJHOYXJGGTR-IFHOVBQLSA-N acetic acid;(2s)-n-[(2r)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-1-[(4r,7s,10s,13s,16s)-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,1 Chemical compound CC(O)=O.C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 MLSVJHOYXJGGTR-IFHOVBQLSA-N 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 7
- 229920000089 Cyclic olefin copolymer Polymers 0.000 description 5
- 239000004713 Cyclic olefin copolymer Substances 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- -1 polyethylene Polymers 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000004922 lacquer Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000002002 slurry Substances 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229940028441 minirin Drugs 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 229920001592 potato starch Polymers 0.000 description 3
- 238000007873 sieving Methods 0.000 description 3
- 238000013112 stability test Methods 0.000 description 3
- FIEYHAAMDAPVCH-UHFFFAOYSA-N 2-methyl-1h-quinazolin-4-one Chemical compound C1=CC=C2NC(C)=NC(=O)C2=C1 FIEYHAAMDAPVCH-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 229960002845 desmopressin acetate Drugs 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920003080 Povidone K 25 Polymers 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 201000010064 diabetes insipidus Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000003475 lamination Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 206010029446 nocturia Diseases 0.000 description 1
- 238000001139 pH measurement Methods 0.000 description 1
- 238000012536 packaging technology Methods 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- KKEYFWRCBNTPAC-UHFFFAOYSA-L terephthalate(2-) Chemical compound [O-]C(=O)C1=CC=C(C([O-])=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
- A61J1/035—Blister-type containers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Preparation (AREA)
- Packages (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
ラクトース(900g,DMV,NL製品Pharmatose 150M)と澱粉(550g,Lyckeby Starkelse AB,SE製品AmylSolVat)を混合し、1mmシーブで篩分けした。リンゴ酸(1.88g)、水(75ml)及びPVP(13.8g,BASF GmbH,DE製品Kollidon(登録商標)25)から構成される造粒液を調製し、これにdDAVP(0.75g;PolyPeptide Laboratories AB,SE製品)とエタノール(225g)を加えた。次に造粒液をラクトース/澱粉混合物に加えた。篩分け(1.4mm)し、20〜25時間40℃で乾燥し、更に篩分け(1.4mm)した後、得られた顆粒をステアリン酸マグネシウム(11.3g,1.0mm篩分け;Peter Greven NV,NL製品)と混合した後、シングルパンチ打錠機(Fette Exacta 1)を使用して7500錠に打錠した。dDAVP 0.1mgを含有する典型的な製造後の錠剤は厚さ3〜4mm及び目標重量192mgの白色凸状卵形(6.8×9.6mm)であった。表面は滑らかで引っ掻き傷や縁部の破損がなく、ラミネーション(所謂キャッピング)傾向もなかった。残留含水率は6.1重量%であった。製造後の錠剤の水スラリーのpHは25℃で4.6であった。乾燥顆粒即ち固形製剤自体としても使用することができる錠剤前駆体のpHは4.3であった。
リンゴ酸を省略した以外は実施例1と同様に錠剤を製造した。製造後の錠剤の水スラリーのpHは25℃で6.6であった。残留含水率は6.1重量%であり、即ち、実施例1の錠剤と意図的に同一にした。
Inpac AB,Lund,SEにより提供される従来のパッケージング技術を使用してブリスターパックを製造した。PVCブリスター(RN23−A,バッチ#26145−1;Riblex Film A/S製品)と蓋材アルミ箔(K7606002,バッチ#771297;前記Alcan Packaging Group製品)を密閉用ヒートシールラッカー(Termolack LA723)と併用した。
使用したPVDCはPerlen Converting AG製品Perlalux−Duplex(バッチ#39942)であり、上記のようなPVCブリスターにコーティングした。蓋材アルミ箔K7606002を使用した。
Claims (8)
- 医薬的に許容可能なアジュバント、希釈剤及び/又はキャリヤーを添加したデスモプレシン又は医薬的に許容可能なその塩の固形製剤を充填したブリスターを含む医薬用ブリスターパックであって、前記固形製剤は1gの前記固形製剤を20℃で2mlの水中でスラリー化したときに測定した場合に3.0〜6.2のpHを提供するように酸を含有しており、前記固形製剤は腸溶コーティングを含まず、
ただし、前記固形製剤は口腔内で10秒以内に崩壊する口腔内分散性医薬製剤ではない、
ことを特徴とするブリスターパック。 - 前記pHが3.5〜5.5である請求項1に記載のブリスターパック。
- 前記pHが4.0〜5.0である請求項2に記載のブリスターパック。
- 前記pHが4.5〜4.8である請求項3に記載のブリスターパック。
- 前記酸が、クエン酸、塩酸、リンゴ酸、ステアリン酸、酢酸、リン酸、アジピン酸、酒石酸、グルタミン酸及びアスパラギン酸から構成される群から選択される請求項1から4のいずれか一項に記載のブリスターパック。
- 前記酸が、クエン酸、塩酸及びリンゴ酸から構成される群から選択される請求項5に記載のブリスターパック。
- 前記ブリスターがPVC、PVC/PVDCブレンド、PE、PP、ポリスチレン、ポリエステル、紙、ポリアミド、PET、COC、アルミ箔及びそのブレンドから選択される材料から構成される請求項1から6のいずれか一項に記載のブリスターパック。
- 前記固形製剤が錠剤、粒状粉末、トローチ剤、カシェ剤、乾燥粉末、カプセル剤及びウェハースシートから構成される群から選択される請求項1から7のいずれか一項に記載のブリスターパック。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03025959.2 | 2003-11-13 | ||
EP03025959A EP1530967B1 (en) | 2003-11-13 | 2003-11-13 | Blister pack and solid dosage form comprising desmopressin |
PCT/EP2004/052940 WO2005046646A2 (en) | 2003-11-13 | 2004-11-12 | Blister pack and solid dosage form comprising desmopressin |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007521327A JP2007521327A (ja) | 2007-08-02 |
JP5180477B2 true JP5180477B2 (ja) | 2013-04-10 |
Family
ID=34429342
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006538867A Active JP5180477B2 (ja) | 2003-11-13 | 2004-11-12 | デスモプレシンを含有するブリスターパック及び固形製剤 |
Country Status (11)
Country | Link |
---|---|
US (1) | US8119161B2 (ja) |
EP (1) | EP1530967B1 (ja) |
JP (1) | JP5180477B2 (ja) |
AT (1) | ATE324869T1 (ja) |
CA (1) | CA2541599C (ja) |
DE (1) | DE60305043T2 (ja) |
DK (1) | DK1530967T3 (ja) |
ES (1) | ES2260563T3 (ja) |
HK (1) | HK1078268A1 (ja) |
PT (1) | PT1530967E (ja) |
WO (1) | WO2005046646A2 (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0210397D0 (en) | 2002-05-07 | 2002-06-12 | Ferring Bv | Pharmaceutical formulations |
PT1530967E (pt) | 2003-11-13 | 2006-09-29 | Ferring Bv | Embalagem blister e uma forma de dosagem solida que compreende desmopressina. |
CA2584456C (en) * | 2006-03-02 | 2008-07-22 | Ferring International Center S.A. | Composition comprising desmopressin |
SE528446C2 (sv) * | 2006-03-02 | 2006-11-14 | Ferring Int Ct Sa | Farmaceutisk sammansättning innefattande desmopressin, kiseldioxid och stärkelse |
EP2254751A4 (en) * | 2008-02-28 | 2013-01-02 | Winpak Heat Seal Packaging Inc | EXTRUSION-COATED SHEET OPEN SHEET FOR STIFF-HULL PACKING |
WO2009143356A1 (en) | 2008-05-21 | 2009-11-26 | Ferring International Center S.A. | Orodispersible desmopressin for increasing initial period of sleep undisturbed by nocturia |
US11963995B2 (en) | 2008-05-21 | 2024-04-23 | Ferring B.V. | Methods comprising desmopressin |
US20100286045A1 (en) | 2008-05-21 | 2010-11-11 | Bjarke Mirner Klein | Methods comprising desmopressin |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1548022A (en) | 1976-10-06 | 1979-07-04 | Wyeth John & Brother Ltd | Pharmaceutial dosage forms |
US4285858A (en) | 1979-10-30 | 1981-08-25 | Mt. Sinai School Of Medicine Of The City University Of N.Y. | Vasopressin analogs |
US4263283A (en) | 1980-05-16 | 1981-04-21 | Ferring Pharmaceuticals, Inc. | Method for prophylaxis and/or treatment of sickle cell disease |
GB2111423B (en) | 1981-12-02 | 1985-06-26 | Wyeth John & Brother Ltd | Making quick-dissolving pills |
ATE14047T1 (de) | 1981-12-11 | 1985-07-15 | Wyeth John & Brother Ltd | Verfahren und vorrichtung zum gefrieren einer fluessigkeit. |
ATE24964T1 (de) | 1981-12-11 | 1987-01-15 | Wyeth John & Brother Ltd | Verfahren zur herstellung von festen formgegenstaenden. |
SE8306367L (sv) | 1983-11-18 | 1985-05-19 | Ferring Ab | Antidiuretiskt verkande farmaceutiskt preparat |
US4863737A (en) | 1985-05-01 | 1989-09-05 | University Of Utah | Compositions and methods of manufacture of compressed powder medicaments |
US4731360A (en) | 1985-08-16 | 1988-03-15 | Merck & Co., Inc. | Acylcarnitines as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal compartments |
US4764378A (en) | 1986-02-10 | 1988-08-16 | Zetachron, Inc. | Buccal drug dosage form |
US6746678B1 (en) | 1991-02-22 | 2004-06-08 | Howard K. Shapiro | Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments |
AU653026B2 (en) | 1991-06-07 | 1994-09-15 | Teikoku Seiyaku Kabushiki Kaisha | Physiologically active polypeptide-containing pharmaceutical composition |
RU2109509C1 (ru) * | 1991-12-24 | 1998-04-27 | Яманути Фармасьютикал Ко., Лтд. | Композиция для буккального введения лекарственного средства и способ ее получения |
US5298256A (en) * | 1992-04-28 | 1994-03-29 | Corint, Ltd. | Desmopressin buccal patch composition |
US5343672A (en) | 1992-12-01 | 1994-09-06 | Scherer Ltd R P | Method for manufacturing freeze dried dosages in a multilaminate blister pack |
SE9300937L (sv) | 1993-03-19 | 1994-09-20 | Anne Fjellestad Paulsen | Komposition för oral administrering av peptider |
SE501677C2 (sv) | 1993-06-18 | 1995-04-10 | Ferring Bv | Biologiskt aktiva vasopressinanaloger, farmaceutiska preparat innehållande dem samt deras användning för framställning av läkemedel |
US5985835A (en) | 1993-12-23 | 1999-11-16 | Ferring B.V. | Desmopressin for nocturia, incontinence and enuresis |
PT710243E (pt) | 1993-06-29 | 2000-11-30 | Ferring Bv | Sintese melhorada de peptidos ciclicos. |
US5482931A (en) * | 1993-06-29 | 1996-01-09 | Ferring Ab | Stabilized pharmaceutical peptide compositions |
US5500413A (en) | 1993-06-29 | 1996-03-19 | Ferring Ab | Process for manufacture of 1-deamino-8-D-arginine vasopressin |
US5674850A (en) | 1993-12-23 | 1997-10-07 | Ferring Ab | High purity desmopressin produced in large single batches |
DK0708657T3 (da) | 1993-06-29 | 2001-10-15 | Ferring Bv | Sammensætninger til nasal administration af desmopression |
SE9400918L (sv) * | 1994-03-18 | 1995-09-19 | Anne Fjellstad Paulsen | Stabiliserad komposition för oral administrering av peptider |
US5849322A (en) | 1995-10-23 | 1998-12-15 | Theratech, Inc. | Compositions and methods for buccal delivery of pharmaceutical agents |
US5763398A (en) | 1996-06-20 | 1998-06-09 | Ferring B.V. | Nasal administration of desmopressin |
US5922680A (en) | 1996-10-23 | 1999-07-13 | Ferring, B.V. | Stabilized composition for oral administration of peptides |
SE9604341D0 (sv) | 1996-11-26 | 1996-11-26 | Ferring Bv | Hepta-peptide oxytocin analogue |
US5976577A (en) | 1997-07-11 | 1999-11-02 | Rp Scherer Corporation | Process for preparing fast dispersing solid oral dosage form |
GB9827292D0 (en) | 1998-12-12 | 1999-02-03 | Univ Strathclyde | Freeze drying |
US20060025387A1 (en) | 1998-12-23 | 2006-02-02 | Cytoscan Sciences Llc | Compositions and methods for the treatment of disorders of the central and peripheral nervous systems |
GB9901819D0 (en) | 1999-01-27 | 1999-03-17 | Scherer Corp R P | Pharmaceutical compositions |
ES2233329T3 (es) | 1999-02-15 | 2005-06-16 | Sumitomo Pharmaceuticals Company, Limited | Comprimidos que se desintegran rapidamente en la cavidad bucal. |
AR014640A1 (es) | 1999-02-23 | 2001-03-28 | Univ Nac Quilmes | UNA COMPOSICíoN FARMACÉUTICA INHIBIDORA DE LA DISEMINACIoN METASTÁSICA DURANTE LA CIRUGíA DE UN TUMOR CANCEROSO, UN PROCEDIMENTO DE PREPARACIoN Y UN KIT PARA UNA FORMULACIoN INYECTABLE. |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US7060708B2 (en) | 1999-03-10 | 2006-06-13 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
US6210699B1 (en) | 1999-04-01 | 2001-04-03 | Watson Pharmaceuticals, Inc. | Oral transmucosal delivery of drugs or any other ingredients via the inner buccal cavity |
GB9908014D0 (en) | 1999-04-08 | 1999-06-02 | Scherer Corp R P | Pharmaceutical compositions |
GB2355454A (en) | 1999-10-20 | 2001-04-25 | Ferring Bv | Antidiuretic agents |
US6264981B1 (en) | 1999-10-27 | 2001-07-24 | Anesta Corporation | Oral transmucosal drug dosage using solid solution |
GB0000079D0 (en) | 2000-01-05 | 2000-02-23 | Ferring Bv | Novel antidiuretic agents |
AT409081B (de) * | 2000-02-16 | 2002-05-27 | Gebro Pharma Gmbh | Stabile, nasal, oral oder sublingual anwendbare pharmazeutische zubereitung |
GB0015601D0 (en) | 2000-06-26 | 2000-08-16 | Ferring Bv | Novel antidiuretic agents |
US6348486B1 (en) | 2000-10-17 | 2002-02-19 | American Home Products Corporation | Methods for modulating bladder function |
RU2708563C2 (ru) | 2001-03-16 | 2019-12-10 | Алза Корпорейшн | Трансдермальный пластырь для введения фентанила |
US6509040B1 (en) | 2001-06-22 | 2003-01-21 | R.P. Scherer Corporation | Fast dispersing dosage forms essentially free of mammalian gelatin |
GB0210397D0 (en) * | 2002-05-07 | 2002-06-12 | Ferring Bv | Pharmaceutical formulations |
DE60307082T4 (de) * | 2002-05-07 | 2015-04-30 | Ferring B.V. | In der mundhöhle dispergierbare phamarzeutische zusammensetzung mit desmopressin |
US20060193825A1 (en) | 2003-04-29 | 2006-08-31 | Praecis Phamaceuticals, Inc. | Pharmaceutical formulations for sustained drug delivery |
US7094545B2 (en) | 2003-04-30 | 2006-08-22 | Ferring Bv | Pharmaceutical composition as solid dosage form and method for manufacturing thereof |
ATE301990T1 (de) | 2003-07-25 | 2005-09-15 | Ferring Bv | Pharmazeutische desmopressin-zubereitung als feste darreichungsform und methode zu ihrer herstellung |
CN1826099B (zh) | 2003-07-25 | 2010-06-09 | 凡林有限公司 | 固体剂型药物组合物及其制造方法 |
EP2322197A2 (en) | 2003-11-10 | 2011-05-18 | Reprise Biopharmaceutics, LLC | Pharmaceutical compositions including low dosages of desmopressin |
PT1530967E (pt) | 2003-11-13 | 2006-09-29 | Ferring Bv | Embalagem blister e uma forma de dosagem solida que compreende desmopressina. |
US7018653B2 (en) | 2003-12-29 | 2006-03-28 | Ferring B.V. | Method for preparing solid dosage form of desmopressin |
US7295874B2 (en) * | 2005-01-06 | 2007-11-13 | Cardiac Pacemakers, Inc. | Intermittent stress augmentation pacing for cardioprotective effect |
JP2008538575A (ja) | 2005-04-22 | 2008-10-30 | ワイス | ベンゾジオキサンおよびベンゾジオキソラン誘導体ならびにそれらの使用 |
SE528446C2 (sv) | 2006-03-02 | 2006-11-14 | Ferring Int Ct Sa | Farmaceutisk sammansättning innefattande desmopressin, kiseldioxid och stärkelse |
-
2003
- 2003-11-13 PT PT03025959T patent/PT1530967E/pt unknown
- 2003-11-13 DE DE60305043T patent/DE60305043T2/de not_active Expired - Lifetime
- 2003-11-13 DK DK03025959T patent/DK1530967T3/da active
- 2003-11-13 AT AT03025959T patent/ATE324869T1/de active
- 2003-11-13 ES ES03025959T patent/ES2260563T3/es not_active Expired - Lifetime
- 2003-11-13 EP EP03025959A patent/EP1530967B1/en not_active Expired - Lifetime
-
2004
- 2004-11-12 US US10/519,715 patent/US8119161B2/en active Active
- 2004-11-12 CA CA2541599A patent/CA2541599C/en not_active Expired - Fee Related
- 2004-11-12 WO PCT/EP2004/052940 patent/WO2005046646A2/en active Application Filing
- 2004-11-12 JP JP2006538867A patent/JP5180477B2/ja active Active
-
2005
- 2005-11-15 HK HK05110206A patent/HK1078268A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
DE60305043T2 (de) | 2006-11-30 |
DE60305043D1 (de) | 2006-06-08 |
ATE324869T1 (de) | 2006-06-15 |
HK1078268A1 (en) | 2006-03-10 |
WO2005046646A2 (en) | 2005-05-26 |
CA2541599A1 (en) | 2005-05-26 |
JP2007521327A (ja) | 2007-08-02 |
CA2541599C (en) | 2011-01-25 |
US20070117759A1 (en) | 2007-05-24 |
US8119161B2 (en) | 2012-02-21 |
WO2005046646A3 (en) | 2007-02-22 |
PT1530967E (pt) | 2006-09-29 |
ES2260563T3 (es) | 2006-11-01 |
DK1530967T3 (da) | 2006-07-03 |
EP1530967B1 (en) | 2006-05-03 |
EP1530967A1 (en) | 2005-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220125734A1 (en) | Stable Solid Formulation of GC-C Receptor Agonist Polypeptide Suitable for Oral Administration | |
US20090281136A1 (en) | Prasugrel pharmaceutical formulations | |
US20140287034A1 (en) | Stable Solid Formulation of a GC-C Receptor Agonist Polypeptide Suitable for Oral Administration | |
EP2691083B1 (en) | Pharmaceutical composition of sitagliptin | |
CA2561856A1 (en) | Compressed composition comprising magnesium salt | |
JP2004525123A (ja) | 経口ペプチド医薬投与形および製造方法 | |
US11534404B2 (en) | Multilayer beads for pharmaceutical use | |
JP2018076372A (ja) | アナグリプチン含有固形製剤 | |
EP2540318B1 (en) | Sustained-release solid preparation for oral use | |
JP3906485B1 (ja) | 薬物包装体 | |
JP5180477B2 (ja) | デスモプレシンを含有するブリスターパック及び固形製剤 | |
EP2948170B1 (en) | Pharmaceutical compositions for treating celiac disease and gluten intolerance | |
JP2022082823A (ja) | 医薬品 | |
JP2007211005A (ja) | 固形製剤用組成物および固形製剤 | |
JP2007185490A (ja) | 薬物包装体 | |
WO2008132756A1 (en) | Stable pharmaceutical compositions of ramipril | |
WO2013058409A1 (en) | Sustained-release preparation | |
JP2021181499A (ja) | 医薬組成物 | |
JP2016222714A (ja) | 医薬 | |
KR101125087B1 (ko) | 약물 포장체 | |
JPWO2003075919A1 (ja) | 塩酸ピルジカイニド含有錠剤(乾式) | |
EA045037B1 (ru) | Фармацевтические составы ингибиторов индоламин-2,3-диоксигеназы | |
JP2021008432A (ja) | 医薬組成物 | |
JP2004073377A (ja) | 固形医薬組成物中の有効成分の安定化方法 | |
JP2018062524A (ja) | 医薬 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20090713 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20090724 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090908 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091207 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091214 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100308 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100406 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100924 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130111 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5180477 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |